Hepatitis C Market Saw Considerable Developments Recently, States GBI Research in Its Study Published at MarketPublishers.com16 Jan 2017 • by Natalie Aster
LONDON – Hepatitis C is characterised by a high rate of global prevalence, and the number of people that suffer from the disease stands at around 130-170 million from pole to pole.
The last several years have seen remarkable developments in treatments for HCV infection. This has led to the intensification of the competition in the market, with a number of oral regimens combining direct-acting antivirals (DAA) from various nonstructural (NS) HCV protein families - NS5A replication complex inhibitors (RCIs), NS3/4A protease inhibitors and NS5B polymerase inhibitors - having been licensed. These novel multimodality therapies have turned out to be extremely popular on the market.
Notwithstanding the entry of these novel treatment modalities, there is a population of patients which do not respond to today’s treatments, or relapse. Additionally, the resistance of HCV to DAAs could also present grounds for concern, as the development of the pressure of selection by the host immune system alongside DAA treatment can possibly result in the outgrowth of drug-resistant viruses. This implies a strong need for pouring money into first-in-class innovation.
In-demand report “Frontier Pharma: Hepatitis C” prepared by GBI Research delves deep in the present-day therapeutic and commercial aspects of the hepatitis C marketplace.
The report gives an all-round overview of the disease, symptoms, epidemiology, risk factors and etiology, pathophysiology, disease progression, complications and co-morbidities, diagnosis, and treatment modes and algorithms, as well as a comprehensive analysis of the marketed products. It offers a discussion of the innovative trends in the hepatitis C pipeline by assessing the therapies based on stage of development, molecular target and molecule type. The study thoroughly evaluates the clinical potential of first-in-class targets, followed by shrewd insights into the most promising early-stage targets. The report offers an evaluation of the first-in-class targets like viral targets and host targets. Furthermore, the deals landscape pertaining to the hepatitis C sector is thoroughly analysed in the report.
More in-demand market research studies by the publisher are available at GBI Research page.